GlassScriptPhysician profile
Laura L Sears
NPI 1942298708
$7,770.63
in general payments reported to CMS, 2019-2025
37 companies · $58.95 in 2025
The $58.95 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,354 · 2020: $1,656 · 2021: $1,376 · 2022: $1,940 · 2023: $1,294 · 2024: $91.95 · 2025: $58.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,444.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,133.98 | 2019-2025 | Botox, Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $715.87 | 2019-2023 | |
| Janssen Biotech, INC. | $614.80 | 2019-2023 | Tremfya |
| Pfizer INC. | $564.11 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $496.67 | 2020-2023 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $481.60 | 2019-2024 | Aklief, Oracea, Twyneo |
| Genzyme Corporation | $465.80 | 2019-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $442.45 | 2019-2023 | Arazlo |
| Leo Pharma INC. | $323.70 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $321.88 | 2019-2023 | |
| Lilly USA, LLC | $301.41 | 2019-2023 | Olumiant, Taltz |
| Sun Pharmaceutical Industries INC. | $300.31 | 2019-2023 | Ilumya |
| Amgen INC. | $227.63 | 2020-2022 | |
| Almirall LLC | $151.33 | 2019-2023 | Seysara, Klisyri |
| Incyte Corporation | $122.17 | 2021-2023 | Opzelura |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $118.08 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $113.78 | 2020 | |
| Nabriva Therapeutics, Plc | $101.06 | 2021-2022 | |
| Epi Health, LLC | $100.20 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $89.76 | 2020-2021 | |
| Journey Medical Corporation | $87.76 | 2019-2023 | |
| Encore Dermatology INC. | $78.57 | 2019-2020 | |
| Ucb, INC. | $53.92 | 2019-2021 | |
| Medimetriks Pharmaceuticals, INC. | $48.47 | 2020 | |
| Tactile Systems Technology INC | $48.31 | 2022-2023 | Entre Plus, Flexitouch Plus |
| Celgene Corporation | $33.06 | 2019 | |
| Biofrontera INC. | $32.99 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.66 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.55 | 2022 | |
| Promius Pharma LLC | $24.43 | 2019 | |
| Arcutis Biotherapeutics, INC. | $20.67 | 2023 | |
| Prugen, INC. Pharmaceuticals | $20.47 | 2019 | |
| Aclaris Therapeutics, INC. | $20.25 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.11 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.24 | 2022 | |
| Genentech USA, INC. | $15.81 | 2022 | |
| Dermira, INC. | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Sears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.